Introduction: Inflammation, insulin resistance,
INTRODUCTION
Essential hypertension (EH) is a substantial public health problem, affecting 25% of the adult population in industrialized societies [1] . This multifactorial and multigenetic disorder is a major risk factor for many common causes of mortality and morbidity including stroke, myocardial infarction, congestive heart failure, and end-stage renal disease [2] . Insulin resistance is seen in more than half of patients with EH [3] .
Despite the important role of EH as a cause of disease, its pathogenesis remains largely unknown.
Abnormalities in endothelial function and morphology appear to play a central role in the pathogenesis of hypertension-related atherosclerosis [4] . Among the mechanisms causing endothelial dysfunction that have been recently implicated in EH is oxidative stress (OS), which may impair endotheliumdependent vasodilatation, inflammation, and insulin resistance [5] . Primed peripheral polymorphonuclear leukocytes (PMNLs) are one of the main types of inflammatory cells; once activated, primed PMNLs release reactive oxygen species (ROS), contributing to OS, lowgrade inflammation, endothelial damage, and atherosclerosis in the long term [6, 7] . Recently, the authors have previously reported that hypertension, renal failure, and diabetes, and in cigarette smoking, which is known to be associated with endothelial dysfunction and accelerated atherosclerosis [8] [9] [10] [11] [12] . The long-acting calcium channel blockers (CCB), widely used in the clinical setting, have been shown to prevent atherosclerosis [13] [14] [15] , among which amlodipine has an antioxidative action in vivo [16] . In the current study, the authors examined the effects of monotherapy using lercanidipine, a vasoselective dihydropyridine CCB that causes systemic vasodilatation by blocking the influx of calcium ions through L-type calcium channels in cell membranes. As a highly lipophilic drug, lercanidipine has a slower onset, longer duration of action, and fewer adverse effects than a number of other CCB [17] . In well-controlled clinical studies, once-daily administration of 10 or 20 mg lercanidipine effectively reduced blood pressure compared with placebo in patients with mild-to-moderate hypertension without affecting heart rate [18] . However, there are no precedent studies that demonstrate the various effects of this drug on systemic and PMNLrelated inflammation, and on insulin resistance over a period of 2 months of treatment. Thus, the objective of the present study was to determine the effect of lercanidipine on these parameters in EH. Sera and plasma were frozen at -20°C for determining the clinical and biochemical characteristics of the participants, and for systemic inflammation parameters.
MATERIALS AND METHODS

Patients
PMNL Priming
Rate of Superoxide Release
The measurements of the rate of superoxide release are based on superoxide dismutase (SOD) inhibitable reduction of 80 lM cytochrome C (Sigma, St. Louis, MO, USA) to its ferrous form [20] . The rate of superoxide release was monitored from 10 6 separated PMNLs, after stimulation with 0.32 9 10 -7 M phorbol 12-myristate 13-acetate (PMA; Sigma, St. Louis, MO, USA), at 22°C for 50 min. This parameter was used as a measure of PMNL priming.
PMNL-Derived Inflammation
WBC and PMNL Counts
Counts of WBC and PMNLs from blood drawn in ethylenediaminetetraacetic acid (EDTA) were performed by an automated cell counter (Coulter STKS Analyzer, Coulter Corporation, Miami, FL, USA) and used as a measure of lowgrade inflammation.
Analysis of Apoptotic PMNLs
Apoptosis was analyzed in whole blood from EH patients and NC subjects of each group by flow cytometry according to Kuypers et al. [21] . Blood samples were assayed for apoptosis after lysis of red blood cells by Q PREP TM (Beckman Coulter, Inc., Galway, Ireland) and incubated with fluorescein isothiocyanate (FITC)-labeled monoclonal antibodies using the Annexin V kit (Bender MedSystems, Vienna, Austria).
PMNLs were defined by forward scatter/side scatter and by R-phycoerythrin (PE)-labeled monoclonal anti-CD16.
Systemic Inflammation
Measurement of Plasma Fibrinogen
Fibrinogen was measured in a Cobas Mira plus instrument (Roche, Mannheim, Germany), in all plasma samples using the K-Assay Ò kit (Kamiya Biomedical Company, Seattle, WA, USA).
Measurement of C-Reactive Protein,
Transferrin, and Albumin C-reactive protein (CRP), transferrin, and albumin were routinely assayed in the biochemistry lab using a Hitachi 917 Automatic Analyzer (Roche Diagnostics, Mannheim, Germany) in separated sera obtained from all EH patients and NC subjects after an overnight fast.
Insulin as a Marker of Insulin Resistance
Fasting serum insulin levels served as a measure for insulin resistance, and were measured using an electrochemiluminescence immunoassay kit (Roche Diagnostics, Mannheim, Germany). Insulin resistance was also verified by homeostasis model assessment-insulin resistance (HOMA-IR) test.
Statistical Analysis
Data are expressed as mean ± SEM. Differences in mean values were tested by two-way analysis of variance (ANOVA) and by the Bonferroni multiple comparison test, using Prism version 3.0 statistical software (GraphPad software, San Diego, CA, USA). Correlations between different study parameters were performed using Pearson correlation coefficients. P\0.05 was considered significant. Table 1 summarizes the clinical and biochemical characteristics of the participants.
RESULTS
Study Population
All studied groups of patients showed similar serum cholesterol, serum creatinine, serum triglycerides, liver enzymes, and serum glucose (Table 1) .
PMNL Priming
Rate of Superoxide Release
Significantly faster rates of superoxide release from PMA-stimulated PMNLs were found in EH patients before and following 2 months of lercanidipine treatment (Table 2) , as compared to NCs (18.2 ± 1.2 nmol/10 6 cells/10 min), reflecting a higher priming state in these groups (EH). Two months of treatment reflected a slight, though significant, decrease in the rate of superoxide release from PMAstimulated PMNLs (Table 2) .
PMNL-Derived Inflammation
WBC and PMNL Counts
EH patients had significantly higher numbers of WBC and PMNLs (Table 2) , as compared to NC subjects (7.2 ± 0.1 and 3.9 ± 0.2 9 10 9 cells/mL, Table 2) .
Percentage of Apoptotic PMNLs
The percentage of apoptotic PMNLs, assayed immediately after blood withdrawal in whole blood, was significantly higher in EH group of patients (Fig. 1) , as compared to NCs (2.8% ± 0.7%). One month of lercanidipine treatment significantly reduced the percentage of apoptotic PMNLs, a reduction that was further amplified after 2 months of treatment.
Systemic Inflammation
Measurement of Plasma Fibrinogen
Plasma fibrinogen levels fell within the upper quartile of the normal range and were higher than the levels of the NC subjects (289 ± 12 mg/ dL). A slight nonsignificant reduction in plasma fibrinogen levels was found after 2 months of lercanidipine treatment ( Table 2) .
Measurement of CRP, Albumin, and Transferrin
Significantly decreased serum CRP levels were shown after 2 months of lercanidipine treatment compared with untreated EH (1.46 ± 0.1 mg/L; Fig. 2 ). Increased serum albumin levels were found in NCs and treated EH patients compared with untreated EH patients, although all fell within normal range. In addition, a significant change was found in the serum transferrin levels of NCs compared with untreated EH (Table 2) .
Insulin as a Marker of Insulin Resistance
Fasting serum insulin levels served as a measure of insulin resistance [9] . Figure 3 shows a significant decrease of serum insulin levels after 2 months of lercanidipine treatment, although levels were still higher than levels in NCs (8.4 ± 0.9 lU/mL) after 2 months of treatment. It has to be emphasized that in these mild-to-moderate untreated EH patients, Plasma fibrinogen levels positively correlated with MAP: r = 0.27, P = 0.007 (n = 101; Fig. 5a ).
However, no correlation could be found between serum CRP levels and MAP: r = 0.05, P = 0.6 (n = 109; Fig. 5b ). CRP C-reactive patients, EH essential hypertension, MAP mean arterial pressure, NC normal control Fig. 6 Correlation between serum insulin levels and MAP. Data refer to values from all EH patients (treated and untreated) and NC subjects (n = 110). EH essential hypertension, MAP mean arterial pressure, NC normal control
[10], which constitute a mortality predictor in hemodialysis patients [22, 23] , and as a predictor for developing chronic kidney disease [24] . In the present study, WBC and PMNL counts were also higher in EH patients, and declined significantly after treatment with lercanidipine, exhibiting a reduction in the PMNL-related lowgrade inflammation.
In parallel, other systemic inflammation markers, such as CRP, fibrinogen, transferrin, and albumin were also assessed. Serum albumin is a negative acute-phase protein whose low level is attributed to inflammation [25] ; although in the normal range, the authors showed a significant increase following lercanidipine treatment. Th reduction in fibrinogen was slight and nonsignificant, and transferrin levels did not change, possibly due to the relatively small number of the patients.
An interesting observation from the present study is the significant decrease in CRP level during treatment with lercanidipine to low levels as observed in NC, which are predictive of reduced cardiovascular risk. Numerous studies have demonstrated that elevated CRP levels and upper quartile of normal levels are highly predictive of an increased incidence of cardiovascular events in healthy males and females [26] [27] [28] . The low-grade inflammation derived from PMNL priming does not correlate with CRP. These findings imply that different processes are involved in inflammation, which need to be further clarified.
In the present study, lercanidipine treatment significantly lowered fasting serum insulin levels. EH patients have higher plasma insulin levels in response to glucose load, whether obese or of normal body weight [29] . This hyperinsulinemia is a consequence of resistance to the effects of insulin on peripheral glucose utilization and to decreased hepatic uptake of insulin [30] . 
